Enrollment is complete in a Phase 2b trial of PHENOGENE-1A for mild-to-moderate ALS. ALS is a progressive disorder in which motor neurons die, with nervous system inflammation thought to play a role.

The ALS Nexus 2026 conference highlighted cutting-edge research, experimental therapies, and advances in care for ALS.

To anyone recently diagnosed with ALS, don’t let anyone else write the ending to your story. There is still life to live, ...

Newly diagnosed ALS patients show significantly higher levels of nano- and microplastics in their cerebrospinal fluid and ...

Researchers are testing a device that safely induces a controlled fever as a possible treatment for ALS. The aim is to stimulate the heat-shock response to help nerve cells clear toxic protein clumps ...

A few months ago, my husband and I decided it was time to replace the mattress set we’d slept on for the past 10 years.

For Emmy award-winning host and New York Times bestselling author Tabitha Brown, joy, gratitude, and hope have guided her ...

A newer set of diagnostic criteria for amyotrophic lateral sclerosis (ALS) was significantly more sensitive at identifying people with the disease than two older diagnostic approaches, a real-world ...

Neurosense Therapeutics is revamping its development plan for PrimeC, the company’s experimental oral therapy for amyotrophic lateral sclerosis (ALS).

When my late husband, Craig, was diagnosed with ALS, we were very naïve and didn’t really know much about the disease. ALS ...

ALN-SOD, an experimental RNA-based therapy being developed for a genetic subtype of amyotrophic lateral sclerosis (ALS) ...

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to CK0803, an experimental T-cell therapy from Cellenkos that’s currently in Phase 1 clinical testing for people with ...